Among several bidders for Cardinal Health Inc.’s China business, Shanghai Pharmaceuticals Holding Co. Ltd. ’s chances to emerge the winner remain uncertain, even as the company has filed its bid in the second round. The bid value is potentially higher than what is being speculated in the media, an investor source with knowledge of the deal told Scrip.
Shanghai Pharma said it submitted the first and second rounds of bids to Cardinal on 21 July and 15 September 2017, respectively
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?